173
Participants
Start Date
August 19, 2019
Primary Completion Date
January 31, 2027
Study Completion Date
January 31, 2027
SCIB1 or iSCIB1+ DNA vaccine
"Participants receive up to 11 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.~Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment."
RECRUITING
Cambridge University Hospitals NHS Foundation Trust, Cambridge
RECRUITING
Velindre University NHS Trust, Cardiff
RECRUITING
The Leeds Teaching Hospitals NHS Trust, Leeds
RECRUITING
Guy's & St Thomas' NHS Foundation Trust, London
RECRUITING
Royal Free London NHS Foundation Trust, London
RECRUITING
The Royal Marsden NHS Foundation Trust, London
RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
East and North Hertfordshire NHS Trust, Northwood
RECRUITING
Nottingham University Hospitals NHS Trust, Nottingham
RECRUITING
Oxford University Hospital NHS Foundation Trust, Oxford
RECRUITING
University Hospital Plymouth NHS Trust, Plymouth
RECRUITING
Lancashire Teaching Hospitals NHS Foundation Trust, Preston
RECRUITING
Sheffield Teaching Hospital NHS Foundation Trust, Sheffield
RECRUITING
University Hospital Southampton NHS Foundation Trust, Southampton
RECRUITING
Somerset NHS Foundation Trust, Taunton
Scancell Ltd
INDUSTRY